Oric Net Tangible Assets from 2010 to 2026
| ORIC Stock | USD 10.03 0.00 0.00% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 255.7 M | Current Value 268.5 M | Quarterly Volatility 154.1 M |
Check Oric Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oric Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 3.2 M or Selling General Administrative of 17.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.14. Oric financial statements analysis is a perfect complement when working with Oric Pharmaceuticals Valuation or Volatility modules.
Oric | Net Tangible Assets | Build AI portfolio with Oric Stock |
Analyzing Oric Pharmaceuticals's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Oric Pharmaceuticals's current valuation and future prospects.
Latest Oric Pharmaceuticals' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Oric Pharmaceuticals over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Oric Pharmaceuticals' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oric Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Oric Net Tangible Assets Regression Statistics
| Arithmetic Mean | 73,564,675 | |
| Geometric Mean | 95,453,279 | |
| Coefficient Of Variation | 209.42 | |
| Mean Deviation | 145,769,971 | |
| Median | (43,611,000) | |
| Standard Deviation | 154,061,227 | |
| Sample Variance | 23734.9T | |
| Range | 379.9M | |
| R-Value | 0.82 | |
| Mean Square Error | 8478.5T | |
| R-Squared | 0.67 | |
| Significance | 0.000066 | |
| Slope | 24,881,111 | |
| Total Sum of Squares | 379757.8T |
Oric Net Tangible Assets History
About Oric Pharmaceuticals Financial Statements
Oric Pharmaceuticals stakeholders use historical fundamental indicators, such as Oric Pharmaceuticals' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Oric Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Oric Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Oric Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Oric Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 255.7 M | 268.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Oric Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Oric Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Oric Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Oric Pharmaceuticals Stock:Check out the analysis of Oric Pharmaceuticals Correlation against competitors. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Will Biotechnology sector continue expanding? Could Oric diversify its offerings? Factors like these will boost the valuation of Oric Pharmaceuticals. Anticipated expansion of Oric directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oric Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Oric Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oric's balance sheet. Smart investors calculate Oric Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Oric Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Oric Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oric Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.